The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.24
Bid: 18.72
Ask: 19.94
Change: 0.45 (2.39%)
Spread: 1.22 (6.517%)
Open: 19.24
High: 19.24
Low: 19.24
Prev. Close: 18.79
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract extension signed

25 Jan 2019 07:00

RNS Number : 0694O
Nanoco Group PLC
25 January 2019
 

25 January 2019

 

NANOCO GROUP PLC

("Nanoco" or the "Group")

 

Contract extension signed

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, today announces that it has signed a contract extension to deliver additional services and materials to an undisclosed US Company (the 'US Company').

In February 2018, Nanoco announced the signing of a Material Development and Supply Agreement with the US Company. Since then, Nanoco has successfully completed a number of technical milestones as well as substantially completing the expansion of the Runcorn facility. Following on from the progress to date, the US Company has now extended the scope of work required from Nanoco.

The contract extension runs from January 2019 to December 2019. During that period, Nanoco will carry out stress testing and process optimization on the new production facility. The majority of revenue is expected to be earned during the period of the agreement, with limited deferrals, and with no contingent or milestone based payments.

 

The Group noted in its Preliminary Results announcement, on 16 October 2018, that revenue was expected to double in the financial year ending 31 July 2019. At that time, approximately £3.0m of revenue was noted as being under contract, with further potential agreements under active discussion. Successful delivery of the services under the contract extension noted above will fully underpin those revenue expectations and also add a similar sum to the backlog of future revenue expected in FY20. The contract extension also underpins the Board's current expectations for operating results and cash flows. The Group remains in active discussion on additional potential commercial agreements with a number of parties that could create upside to these expectations.

 

Michael Edelman, Chief Executive of Nanoco, said:

 

"We are pleased to announce today's contract extension with our US Customer. This extension is a clear demonstration of Nanoco's unique capabilities and value proposition with respect to designing and producing complex nano-materials.

 

"We are proud to be innovators in the development of quantum dots and other nano-materials, always improving their quality and performance, with extensive intellectual property and specialist knowledge that gives us a clear competitive lead in this technology. We look forward to further strengthening and deepening the relationship with the US Customer."

 

This announcement contains inside information as defined in EU Regulation No. 596/2014 and is in accordance with the Group's obligations under Article 17 of that Regulation.

 

The person responsible for arranging the release of this announcement on behalf of the Group is Brian Tenner, Chief Operating Officer and Chief Financial Officer.

 

For further information, please contact:

Nanoco Group PLC:

Michael Edelman, CEO +44 (0) 161 603 7900

Brian Tenner, COO & CFO +44 (0) 161 603 7900

Caroline Watson, Investor Relations Manager +44 (0) 7788 897 357

cwatson@nanocotechnologies.com

 

MHP Communications: +44 (0) 20 3128 8570

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com

 

Notes for editors:

 

About Nanoco Group plcNanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display and Electronics markets. One of the interesting properties of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTUSORRKAAAUUR
Date   Source Headline
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.